Stocks · News reference
Tarsus Pharmaceuticals To Acquire Alkeus Pharmaceuticals, A Closely Held Biotech Firm Developing Gildeuretinol, An Investigational Once-Daily Oral Therapy For Stargardt Disease; Terms Not Disclosed
Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of the largest inherited
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Alkeus Pharmaceuticals Receives Orphan Drug Designation From Japan's Ministry Of Health, Labour, And Welfare For Oral Gildeuretinol To Treat Stargardt Disease
Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100
Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the price target from $97 to $100.
Tarsus Pharmaceuticals Q2 EPS $(0.43) Misses $(0.20) Estimate, Sales $173.912M Beat $169.677M Estimate
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.20) by 115 percent. This is a 10.42 percent increase over losses of $(0.48) per